

## Strategic Research & Innovation Committee

## minutes

### Minutes of the Strategic Research & Innovation meeting held on 12<sup>th</sup> December 2023

<b>Present:</b>	Bob Burgoyne	Non-Executive Director (Chair)
	Louise Robson	Non-Executive Director
	Prof Jay Wright	Clinical Lead for Research and Director of Research & Innovation
	Karen Edge	Chief Finance Officer
	Keith Wilson	Patient Research Ambassador
	Catarina Teige	Interim Deputy Director of Research & Innovation
	Jennifer Crooks	Deputy Director of Research & Innovation
	Jonathan Mathews	Chief Operating Officer
<b>In Attendance:</b>	Mark Bellis	
	Jennifer Ohlsson	Senior Executive Assistant (Minutes)
<b>Apologies for Absence:</b>	Jane Tomkinson	Chief Executive Officer
	Prof Raphaela Kane	Pro Vice Chancellor, Faculty of Health, LJMU
	Jonathan Develing	Director of Strategic Partnerships
	Prof Reecha Sofat	Head of Department Pharmacology and Therapeutics, University of Liverpool

#### 1. Apologies for Absence

Apologies noted above.

#### 2. Declarations of Interest

No declarations of Interest noted at this meeting.

#### 3. Minutes of the previous meeting on 11<sup>th</sup> September 2023

Minutes of the previous meeting on 11<sup>th</sup> September were agreed as an

#### Action

accurate record of the meeting.

#### **4. Action log**

**Action 1:** Research Strategy implementation plan due in February 2024.

#### **5. Research Finance Report**

JW presented an overview of the research finance report and noted that the CRN income amount received is in line with S4 statement and the current allocation is £430I including research scholars payable to other departments.

Income from deferred accounts to cover staff is overbudget due to income for ad-hoc non-pay expenses funded by deferred accounts.

Trial income is slight over year to date which is a reversal from previous months. Work is continuing to ensure that the information held on EDGE is current and correct.

Due to the level of accrued income from EDGE plus invoices raised, £125k year to date has been deferred to the Research,

Pay is slightly overspent due to short term over-lapping of posts following maternity leave.

The non-pay year to date underspend primarily related to technical adjustments from 2022-23 year-end and in year underspends of miscellaneous expenditure.

JW also updated colleagues on the recruitment of the band 5 Finance Officer. KE added that this is a fixed term contract that would be under review for recurrent post.

Comments and questions were welcomed, and KE noted the good position within research and credit the senior leadership for recovering the position.

Chair queried whether the Trust were actively looking for partners to bring in commercial income. JC confirmed that the Trust is consistently approached for commercial research and that the Trust also have leads at the CRN that will identify research. JC added that performance is key to attracting more research.

Further discussion took place on commercial research and MB queried whether there is a framework for when there is a financial hit. JC confirmed that there is a meeting each week to discuss the study impact, and there is a hope to strengthen this process. JW agreed that work is being done on the representation at the Operational R&I meetings and this is ongoing.

#### **6. Partnership working and updated from partners**

Chair raised the review of LCCS and informed colleagues that the first meeting was in October and the Terms of Reference was agreed. At

the next meeting, themes will be discussed to expand the scope of LCSS. LCSS performance will be reported to the Strategic R&I Committee. JW informed colleagues that the BHS application for the Centre of Excellence was unsuccessful but there is a chance to go for accelerator funds in January 2024.

MB provided an update on LJMU and noted that they have successfully gone through the LCCS review process.

JC also informed colleagues that a number of grants have gone through recently with the partners. John Field with UoL and Tom Fairburn with BHF.

JW also raised the CRF facility based at LUHFT and informed colleagues that LHCH is the latest member and there is lots of work ongoing. This is a great opportunity to be part of a high quality centre.

### **7. Research news and key successes**

KW raised LCSS and noted that patients don't recognise that LCSS is an organisation. KW asked whether this can be looked at, so that patients are aware. Chair agreed that this needs to move forward. JW agreed that this would be ideal to be covered in members matters and the weekly bulletin.

MB raised a query on whether there is a culture of learning from the grants that were not achieved. JC confirmed that this goes to the Joint Research Office, where BI specialists will collate this data, so that there is learning.

JW informed colleagues that he has been invited to give a lecture in Berlin as LHCH has been cited by the ESC the largest remote pacing follow up centre in Europe.

JC also informed colleagues that LHCH are recruiting for the targeted vaccination study. JC also noted that LHCH will be one of first UK recruits for the ASPIRE study. It was noted that the Trust is currently doing well for recruitment.

### **8. Report on Innovation Agenda**

BB noted that there was a presentation at the previous meeting. It was agreed to defer this item to the February meeting, where a report will be sent.

LR noted that the innovation presentation was a first draft and asked whether there was a session held with the wider leadership team. JM confirmed that this did get presented at the Clinical Leaders Day.

### **9. Minutes from the last operational R&I Committee**

Colleagues were asked to note the Operational R&I Committee minutes circulated prior to the meeting and there were no further comments or questions.

**10. Strategic R&I Committee Terms of Reference**

Colleagues were asked to note the Strategic R&I Committee Terms of Reference. It was noted that there will be a formal review in February.

**11. AoB**

KW raised the recent news that Jane Tomkinson is leaving LHCH and would like to see assurances that new CEO would support the research activity in the Trust.

**Date and time of next meeting:**

Tuesday 27<sup>th</sup> February 2023, 3.00pm – 4.30pm, MS Teams